Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New antifungal agents.

J R Graybill1

  • 1University of Texas Health Science Center, San Antonio 78284.

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
|May 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment.

The Journal of antimicrobial chemotherapy·2008
Same author

Voriconazole in the treatment of fungal eye infections: a review of current literature.

The British journal of ophthalmology·2008
Same author

Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2008
Same author

Control of a Candida glabrata prosthetic endovascular infection with posaconazole.

Medical mycology·2006
Same author

Experimental murine model of disseminated Pseudallescheria infection.

Medical mycology·2002
Same author

Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis.

The British journal of ophthalmology·2002
Same journal

Consensus-based evaluation of RIDASCREEN<sup>®</sup> TB ELISA compared with two interferon-gamma release assays in a low-incidence setting.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2026
Same journal

A review of bloodstream infections-pathogens, pathogenesis, diagnostic strategies, treatment methods-challenges and future aspects.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2026
Same journal

Adaptive susceptibility shifts in Candidozyma auris following biocidal exposure: Exploratory effects on antifungal and biocidal susceptibility.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2026
Same journal

Prevalence and risk factors of sexually transmitted infections in women in eleven hospitals in two low-income countries: a cross-sectional study.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2026
Same journal

Tetracycline for Helicobacter pylori eradication: a narrative review from quadruple to dual therapy.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2026
Same journal

Breaking barriers: Implementation of a tuberculosis preventive treatment protocol among newly eligible populations with promising results.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2026
See all related articles

New antifungal drugs offer alternatives to older treatments like amphotericin B, addressing rising needs due to immunosuppression and AIDS. This review focuses on novel antifungal agents from the last decade.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Amphotericin B has been the primary systemic antifungal for over 20 years but has limitations including parenteral administration and toxicity.
  • The emergence of AIDS and increased use of immunosuppressive agents have highlighted the need for new antifungal treatments.
  • Recent advances include the development of azole antifungals and entirely new classes of agents.

Purpose of the Study:

  • To review novel antifungal drugs developed in the past ten years.
  • To discuss the impact of new antifungal agents on treating systemic mycoses.
  • To highlight the growing need for effective antifungal therapies.

Main Methods:

  • Literature review focusing on antifungal drug development over the last decade.

Related Experiment Videos

  • Analysis of new antifungal classes, including imidazoles and triazoles.
  • Exclusion of developments in polyenes and flucytosine.

    • Main Results:

    • Significant advancements in antifungal drug discovery have occurred in the last ten years.
    • Second-generation imidazole and third-generation triazole antifungals have emerged.
    • Entirely new classes of antifungal agents are now available.

    Conclusions:

    • The development of new antifungal drugs is timely, addressing critical unmet needs in treating systemic fungal infections.
    • The expanding arsenal of antifungal therapies offers improved options for patients, particularly those who are immunocompromised.
    • Continued research and development in antifungal pharmacotherapy are essential.